GC
MIRM icon

Globeflex Capital’s Mirum Pharmaceuticals MIRM Stock Holding History

Globeflex Capital’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,256
Closed -$178K – 436
2025
Q4 		$178K Buy
+2,256
New +$162K 0.03% 310

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Globeflex Capital's MIRM Position: Q1 2026 in Review

Globeflex Capital sold out of Mirum Pharmaceuticals (MIRM) in Q1 2026, closing a stake of 2,256 shares — an estimated $178K sold.

Globeflex Capital first reported a position in MIRM in Q4 2025 and held it in 1 quarter. The position peaked at $178K in Q4 2025. 311 funds tracked by Wall St. Rank hold MIRM as of Q1 2026.

  • Globeflex Capital reported no remaining Mirum Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Globeflex Capital sold 2,256 Mirum Pharmaceuticals shares in Q1 2026, an estimated $178K.
  • Globeflex Capital first reported a position in Mirum Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Globeflex Capital's Mirum Pharmaceuticals position peaked at $178K in Q4 2025.
  • 311 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2026.

Based on Globeflex Capital's 13F filing for Q1 2026, filed 13 May 2026.